Similar articles

• Serum androgens: associations with prostate cancer risk and hair patterning.

  Demark-Wahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Lobaugh B, Mathias BJ, Strigo TS, Paulson DF. Demark-Wahnefried W, et al. J Androl. 1997 Sep-Oct;18(5):495-500. J Androl. 1997. PMID: 9349747
• Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

  Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T. Massengill JC, et al. J Urol. 2003 May;169(5):1670-5. doi: 10.1097/01.ju.0000062674.43964.d0. J Urol. 2003. PMID: 12686805
• Hormonal predictors of prostate cancer.

  Sofikerim M, Eskicorapci S, Oruç O, Ozen H. Sofikerim M, et al. Urol Int. 2007;79(1):13-8. doi: 10.1159/000102906. Urol Int. 2007. PMID: 17627161
• Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

  Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Cookson MS, et al. J Urol. 2007 Feb;177(2):540-5. doi: 10.1016/j.juro.2006.10.097. J Urol. 2007. PMID: 17222629 Review.
• Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.

  Moul JW, Zlotta AR. Moul JW, et al. BJU Int. 2005 Feb;95(3):285-90. doi: 10.1111/j.1464-410X.2005.05284.x. BJU Int. 2005. PMID: 15679779 Review. No abstract available.